A unique phenotype of acquired Glanzmann thrombasthenia due to non‐function‐blocking anti‐αIIbβ3 autoantibodies
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.14323
Abstract: Essentials Acquired Glanzmann thrombasthenia (aGT) is generally caused by function‐blocking antibodies (Abs). We demonstrated a unique aGT case due to marked reduction of αIIbβ3 with anti‐αIIbβ3 Abs. The anti‐αIIbβ3 Abs of the patient did not… read more here.
Keywords: function blocking; acquired glanzmann; anti iib; glanzmann thrombasthenia ... See more keywords
A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant.
Sign Up to like & getrecommendations! Published in 2018 at "Blood advances"
DOI: 10.1182/bloodadvances.2017015552
Abstract: Thrombin activates human platelets via 2 protease-activated receptors (PARs), PAR1 and PAR4, both of which are antithrombotic drug targets: a PAR1 inhibitor is approved for clinical use, and a PAR4 inhibitor is in trial. However,… read more here.
Keywords: par4 variant; function blocking; par4; antibody ... See more keywords
Preclinical validation of a novel metastasis‐inhibiting Tie1 function‐blocking antibody
Sign Up to like & getrecommendations! Published in 2020 at "EMBO Molecular Medicine"
DOI: 10.15252/emmm.201911164
Abstract: The angiopoietin (Ang)–Tie pathway has been intensely pursued as candidate second‐generation anti‐angiogenic target. While much of the translational work has focused on the ligand Ang2, the clinical efficacy of Ang2‐targeting drugs is limited and failed… read more here.
Keywords: function blocking; metastasis; tie1; tie1 function ... See more keywords